Adverse outcome pathway for pregnane X receptor-induced hypercholesterolemia

Arch Toxicol. 2023 Nov;97(11):2861-2877. doi: 10.1007/s00204-023-03575-4. Epub 2023 Aug 29.

Abstract

Pharmaceuticals and environmental contaminants contribute to hypercholesterolemia. Several chemicals known to cause hypercholesterolemia, activate pregnane X receptor (PXR). PXR is a nuclear receptor, classically identified as a sensor of chemical environment and regulator of detoxification processes. Later, PXR activation has been shown to disrupt metabolic functions such as lipid metabolism and recent findings have shown PXR activation to promote hypercholesterolemia through multiple mechanisms. Hypercholesterolemia is a major causative risk factor for atherosclerosis and greatly promotes global health burden. Metabolic disruption by PXR activating chemicals leading to hypercholesterolemia represents a novel toxicity pathway of concern and requires further attention. Therefore, we constructed an adverse outcome pathway (AOP) by collecting the available knowledge considering the molecular mechanisms for PXR-mediated hypercholesterolemia. AOPs are tools of modern toxicology for systematizing mechanistic knowledge to assist health risk assessment of chemicals. AOPs are formalized and structured linear concepts describing a link between molecular initiating event (MIE) and adverse outcome (AO). MIE and AO are connected via key events (KE) through key event relationships (KER). We present a plausible route of how PXR activation (MIE) leads to hypercholesterolemia (AO) through direct regulation of cholesterol synthesis and via activation of sterol regulatory element binding protein 2-pathway.

Keywords: AOP; Cholesterol; Hypercholesterolemia; PCSK9; PXR; SREBP2.

Publication types

  • Review

MeSH terms

  • Adverse Outcome Pathways*
  • Humans
  • Hypercholesterolemia*
  • Lipid Metabolism
  • Pregnane X Receptor
  • Risk Assessment

Substances

  • Pregnane X Receptor